Exact Sciences
EXAS
$68.22
Share price
-1.36%
Change (1 day)
43.35%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Revenue for Exact Sciences (EXAS)
Revenue in 2023 (TTM): $2.30 B
According to Exact Sciences's latest financial reports the company's current revenue (TTM) is $2.30 B. In 2022 the company made a revenue of $2.08 B an increase over the years 2021 revenue that were of $1.76 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exact Sciences from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $2.30 B | 10.38% |
| 2022 | $2.08 B | 17.95% |
| 2021 | $1.76 B | 18.49% |
| 2020 | $1.49 B | 70.19% |
| 2019 | $0.87 B | 92.82% |
| 2018 | $0.45 B | 70.86% |
| 2017 | $0.26 B | 167.66% |
| 2016 | $99.37 M | 151.99% |
| 2015 | $39.43 M | 2093.38% |
| 2014 | $1.79 M | -56.61% |
| 2013 | $4.14 M | 0% |
| 2012 | $4.14 M | -0.46% |
| 2011 | $4.16 M | -22.1% |
| 2010 | $5.34 M | 12.32% |
| 2009 | $4.75 M | |
| 2007 | $2.93 M | -38.21% |
| 2006 | $4.75 M | 11.76% |
| 2005 | $4.25 M | -13.88% |
| 2004 | $4.93 M | 70.11% |
| 2003 | $2.9 M | 223.41% |
| 2002 | $0.89 M | 1663.25% |
| 2001 | $0.05 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $48.63 B | 2,014.14% | 🇫🇷 France |
 Veracyte VCYT | $0.32 B | -85.72% | 🇺🇸 USA |
 Antares Pharma ATRS | $0.18 B | -92.00% | 🇺🇸 USA |
 Myriad Genetics MYGN | $0.69 B | -69.62% | 🇺🇸 USA |
 Biocept
BIOC | -$3.44 M | -100.15% | 🇺🇸 USA |